Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations

Study Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of TYRA-300 in cancers with FGFR3 activating gene alterations, including locally advanced/metastatic urothelial carcinoma of the bladder and urinary tract and other advanced solid tumors.

Conditions

Locally Advanced Urothelial Carcinoma Metastatic Urothelial Carcinoma Solid Tumor Urothelial Carcinoma Solid Tumor, Adult Bladder Cancer Non-muscle-invasive Bladder Cancer FGFR3 Gene Mutation FGFR3 Gene Alteration Advanced Solid Tumor Advanced Urothelial Carcinoma Urinary Tract Cancer Urinary Tract Tumor Urinary Tract Carcinoma

Interventions / Drugs

TYRA-300

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment310 participants

Primary Completion—

Lead SponsorTyra Biosciences, Inc

Data Retrieved2026-04-11 04:30:22.593391+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.